Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

@article{Mattmann2011InhibitionOA,
  title={Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.},
  author={Margrith E. Mattmann and Sydney L. Stoops and Craig W Lindsley},
  journal={Expert opinion on therapeutic patents},
  year={2011},
  volume={21 9},
  pages={
          1309-38
        }
}
INTRODUCTION Akt plays a pivotal role in cell survival and proliferation through a number of downstream effectors; unregulated activation of the PI3K/PTEN/Akt pathway is a prominent feature of many human cancers. Akt is considered an attractive target for cancer therapy by the inhibition of Akt alone or in combination with standard cancer chemotherapeutics. Both preclinical animal studies and clinical trials in humans have validated Akt as an important target of cancer drug discovery. AREA… CONTINUE READING
Highly Cited
This paper has 17 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-8 of 8 citations